Group 1 - The core point of the article is that Xianle Health (300791.SZ) plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and accelerate overseas business development [1][4] - The company has appointed Deloitte as the auditing firm for the H-share listing [1] - Xianle Health provides comprehensive solutions for the global nutrition and health food industry, including research, product development, manufacturing, packaging, logistics, and marketing support [4] Group 2 - For the first three quarters of 2025, Xianle Health achieved total revenue of 3.291 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of 260 million yuan, up 8.53% [4] - As of the end of the reporting period, the company's cash and cash equivalents were 542 million yuan, slightly down from 556 million yuan in the same period last year, while accounts receivable increased by 19.37% to 829 million yuan [4] - The accounts receivable accounted for 255.14% of the latest annual net profit, indicating a significant increase in receivables relative to profit [4] Group 3 - In the first half of 2025, Xianle Health's revenue in China was 818 million yuan, showing a year-on-year decline of 1.63% [5] - The company noted that the demand side is driven by generational changes and refined scenarios, while the supply side is undergoing structural reshaping from 2022 to 2024 [5] - Some fundraising investment projects have been postponed, including the "Digital Information Construction Project," which has been delayed by one year to December 31, 2026 [5]